Lhasa Limited shared knowledge shared progress
Home > Library > Search the Library >
Loading...

Publications

Jump to results
Authors
Publication Type
Publication Year
Related Products
Reset
New search
Publications search results
TitlePublishedTypeProducts
Could the Lhasa Cloud be the best hosting option for you? (Infographic)pdf fileMirabilisViticKaptis
2021 Webinar | Accessing vital sources of long-term carcinogenicity study data with Lhasa’s Carcinogenicity Database – An update and an overview - RecordingLhasa Carcinogenicity Database
2021 Webinar | Accessing vital sources of long-term carcinogenicity study data with Lhasa’s Carcinogenicity Database – An update and an overview - Slidespdf fileLhasa Carcinogenicity Database
QSAR 2021 Addressing the global challenge of N-nitrosamine impurity assessmentpdf fileDerek NexusMirabilisSarah NexusVitic
QSAR 2021 - leveraging data from multiple sources to build QSARs through curation and federated learning in Effiris.pdf fileEffiris
QSAR 2021 Is the bacterial reverse mutation assay an accurate predictor for N-nitrosamine carcinogenicitypdf fileVitic
Predicting N-Nitrosamine Activity from SARpdf fileDerek NexusSarah NexusLhasa Carcinogenicity DatabaseNitrites in Excipients
Effiris_Improving in silico secondary pharmacology profiling using federated QSAR modelspdf fileEffiris
Managing the risk of nitrosamine impurities
Quantifying the nitrosamine potency distributionpdf fileLhasa Carcinogenicity Database
A collaborative benchmarking study to evaluate the newly released Zeneth 8pdf fileZeneth
In silico prediction of N-nitrosamine degradants in APIs that possess a secondary or tertiary amine functional grouppdf fileZeneth
1. Qualifying impurities and degradation products: Anvisa's experience and technical improvement - Maria Rodrigues (Slides)pdf file
1. Qualifying impurities and degradation products: Anvisa's experience and technical improvement - Maria Rodrigues (Video)Zeneth
2. Risk assessment of potential mutagenic impurities in anti-hypertensive drug products approved in Brazil - Fernanda Waechter (Slides)pdf fileZeneth
2. Risk assessment of potential mutagenic impurities in anti-hypertensive drug products approved in Brazil - Fernanda Waechter (Video)Zeneth
3. Case studies on the qualification of impurities - Mariah Ultramari (Slides)pdf fileZeneth
3. Case studies on the qualification of impurities - Mariah Ultramari (Video)Zeneth
Use of less-than-lifetime (LTL) durational limits for nitrosamines: Case study of N-Nitrosodiethylamine (NDEA)
Data Sharing Projects using Vitic [an infographic]pdf fileAromatic AminesAI/PDE Data Sharing ProjectElemental ImpuritiesExcipientsIntermediatesNitrites in ExcipientsVitic
Enhancing carbon acid pKa prediction by augmentation of sparse experimental datasets with accurate AIBL (QM) derived valuesZeneth
Development of an Adverse Outcome Pathway Network to Support an Integrated Approach to Testing and Assessment of Carcinogenic Risk - SOT 2021 Presentation Slidespdf fileKaptisDerek Nexus
Systematic analysis of protein targets associated with adverse events of drugs from clinical trials and postmarketing reports
Development of an Adverse Outcome Pathway Network to Support an Integrated Approach to Testing and Assessment of Carcinogenic Risk - PETA Science Consortium Webinar Slidespdf fileKaptis
The eTRANSAFE Project on Translational Safety Assessment through Integrative Knowledge Management: Achievements and PerspectiveseTRANSAFE
  • Linked In
  • Twitter
  • Instagram
  • Facebook

© 2023 Lhasa Limited | Registered office: Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK Tel: +44 (0)113 394 6020
VAT number 396 8737 77 | Lhasa Limited is registered as a charity (290866)| Company Registration Number 01765239 (England and Wales).